Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;70(3):243-6.
doi: 10.1016/j.mjafi.2014.01.001. Epub 2014 Apr 26.

Drug-eluting balloon: Initial experience in patients with in-stent restenosis (ISR)

A J Swamy  1 , Anil Kumar  2 , G Keshavamurthy  1 , D S Chadha  3
Affiliations

Drug-eluting balloon: Initial experience in patients with in-stent restenosis (ISR)

A J Swamy et al. Med J Armed Forces India. 2014 Jul.

Abstract

Background: In-stent restenosis is the most important limitation of modern coronary angioplasty. Drug-eluting stents solve this problem but at the cost of late stent thrombosis and longer duration of dual-antiplatelet therapy. Drug-eluting balloon (DEB) technology is now available and offers an attractive option for treatment of restenosis.

Methods: A cohort of 20 patients with in-stent restenosis after stenting were treated with a drug-eluting balloon and were followed up clinically and angiographically for 6 months.

Results and conclusion: Procedural success was achieved in all patients. 6 month clinical follow-up was available for all and 6 month angiographic follow up for 17 patients. On 6 month follow-up, 5 of the 20 patients had recurrence of angina and 4 patients had angiographic restenosis (2 focal, 2 diffuse). The mean Canadian Cardiovascular Society angina score improved significantly from 3.1 to 1.1. DEB offers a novel method of treatment for patients with in-stent restenosis with a good safety and efficacy profile.

Keywords: Angina score; Drug-eluting balloon; In-stent restenosis.

PubMed Disclaimer

References

    1. Brower V. Stents and biology combination for restenosis. Nat Biotechnol. 1996;14:422. - PubMed
    1. Farb A., Weber D.K., Kolodgie F.D., Burke A.P., Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980. - PubMed
    1. Kirtane A.J., Gupta A., Iyengar S. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198–3206. - PubMed
    1. Nakazawa G., Vorpahl M., Finn A.V., Narula J., Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Cardiovasc Img. 2009;2:625–628. - PubMed
    1. Finn A.V., Nakazawa G., Joner M. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500–1510. - PubMed

LinkOut - more resources